Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease

Many patients treated with intravenous immunoglobulin (IVIg) are >60 years of age. Tolerability has yet to be demonstrated in this age group.

[1]  M. Lunn,et al.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. , 2016, The Cochrane database of systematic reviews.

[2]  C. Yiannikas,et al.  Significant dermatological side effects of intravenous immunoglobulin , 2013, Journal of Clinical Neuroscience.

[3]  Y. Rajabally,et al.  Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? , 2013, Journal of Neurology.

[4]  E. Gelfand.  Intravenous immune globulin in autoimmune and inflammatory diseases. , 2012, The New England journal of medicine.

[5]  Stefano Tamburin,et al.  Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial , 2012, The Lancet Neurology.

[6]  A. Rae-Grant,et al.  Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders , 2012, Neurology.

[7]  H. Franssen,et al.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies , 2012, Nature Reviews Neurology.

[8]  C. Lacroix,et al.  Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study. , 2011, Revue neurologique.

[9]  Y. Rajabally,et al.  Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study , 2011, Journal of the Neurological Sciences.

[10]  G. Vercellotti,et al.  Haemolysis after treatment with intravenous immunoglobulin due to anti‐A , 2011, Transfusion medicine.

[11]  C. Karam.  Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy , 2010, Neurology.

[12]  H. Hartung,et al.  Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. , 2010, Archives of neurology.

[13]  P. Bergh,et al.  European Federation of Neurological Societies / Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision Members , 2010 .

[14]  K. Abdel-Kader,et al.  Acute kidney injury in the elderly. , 2009, Clinics in geriatric medicine.

[15]  L. Melton,et al.  Incidence and prevalence of CIDP and the association of diabetes mellitus , 2009, Neurology.

[16]  R. D. de Haan,et al.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. , 2009, The Cochrane database of systematic reviews.

[17]  N. Gilhus,et al.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases , 2008, European journal of neurology.

[18]  R. Padmore,et al.  Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis , 2008, Transfusion.

[19]  H. Hartung,et al.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.

[20]  G. Sobue,et al.  Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  M. Inanç,et al.  Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases , 2007, Clinical Rheumatology.

[22]  A. Chiò,et al.  Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[23]  A. Achiron,et al.  Safety of intravenous immunoglobulin (IVIG) therapy. , 2007, Autoimmunity reviews.

[24]  I. Marie,et al.  Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.

[25]  Y. Shoenfeld,et al.  Review: intravenous immunoglobulin therapy and thromboembolic complications , 2005, Lupus.

[26]  Y. Shoenfeld,et al.  Intravenous immunoglobulin and the kidney--a two-edged sword. , 2004, Seminars in arthritis and rheumatism.

[27]  R. Benecke,et al.  Therapy with Intravenous Immunoglobulins: Complications and Side-Effects , 2003, European Neurology.

[28]  M. Smolka,et al.  Side effects of intravenous immunoglobulins in neurological autoimmune disorders , 2003, Journal of Neurology.

[29]  M. Cartwright,et al.  The clinical features of 16 cases of stroke associated with administration of IVIg , 2003, Neurology.

[30]  M. Yaron,et al.  Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases , 2000, Annals of the rheumatic diseases.

[31]  P. Macaskill,et al.  Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia , 1999, Annals of neurology.

[32]  F. Chédru,et al.  Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy , 1999, Neurology.

[33]  A. Achiron.  Complications of intravenous immune globulin treatment in neurologic disease , 1997, Neurology.

[34]  T. Bertorini,et al.  Complications of intravenous gammaglobulin in neuromuscular and other diseases , 1996, Muscle & nerve.

[35]  F. Mastaglia,et al.  Intravenous immunoglobulin for multifocal motor neuropathy , 1992, The Lancet.

[36]  P. Dyck,et al.  Neuropathy associated with monoclonal gammopathies of undetermined significance , 1991, Annals of neurology.